% | $
Quotes you view appear here for quick access.

Nokia Corporation Message Board

roosterly9 46 posts  |  Last Activity: 2 hours 44 minutes ago Member since: Nov 5, 2003
  • From what we hear, investors are sending in withdrawal notices to hedge funds forcing them to sell the VRX shares, every press is focused on bad news. I don't like this company for what they have done contributing to the drug inflation, but that was the past, now we have a value stock. I do not believe for a minute that bond holders will push this company to bankruptcy, they have nothing to gain by doing that, VRX has a very healthy cash flow to service it's debt many times over, they will survive and at PE of less than 3, it is hard not to see value here.Remember Imclone controversy, that drove the stock from 50 to single digit only to come back and be taken over at $70. Concentrate on drugs baby, they work, they sell, sales is growing, go against the negative press, the issues on hand are not bad enough to warrant such a low share price.

  • Reply to

    There is huge value here

    by roosterly9 Apr 3, 2016 7:07 AM
    roosterly9 roosterly9 Apr 3, 2016 12:18 PM Flag

    Nonesense, Jublia weekly TRX are going gangbusters, it has grown to 0ver TRX of 17000 in US, and over 100,000 weekly TRX in EU, do you realize how big is that. As far as not working, you need to apply the medication for about a year allowing healthy nail to grow, you will not know if it is working or not until the bad nail is grown away.

  • Reply to

    There is huge value here

    by roosterly9 Apr 3, 2016 7:07 AM
    roosterly9 roosterly9 Apr 3, 2016 12:01 PM Flag

    I don't know who you are addressing, I have made nothing but money on this stock, used to own it when it was Biovail, got out before the latest big drop, and recently got in at $26, please don't feel sorry for me.

  • If you need to be assured that VRX is way undervalued, and stock not only will survive, but perhaps more than triple within a year, look at prescription levels and trends. This company has bought trophy drugs that have huge sales and are growing, just look at weekly prescription numbers and it's growth rate on Jublia. I admit there are problems, but you do not want to lose the sight of the facts that earnings are going to be there because sales are there, and if earnings are there, then that is what rules at the end, not the negative sentiment that exists now.

  • Reply to


    by l00king2retire Apr 1, 2016 5:54 PM
    roosterly9 roosterly9 Apr 2, 2016 12:11 AM Flag

    How do you know 17 million shares have been converted? I would actually be a little worried if shares are converted. There is no reason to convert your shares before deadline unless you want to sell your shares, convertible bonds are safer than common shares, in case of a bankruptcy bonds holder have priority over stock holders, therefore you hold to your bonds unless you want to convert and sell you shares.

  • Reply to


    by davecarmen48 Apr 1, 2016 2:52 PM
    roosterly9 roosterly9 Apr 2, 2016 12:02 AM Flag

    I hate to throw water on your fire, but have you checked the side effects of the drug, I think patients are not tolerating the drug, and as such we have low refill, and doctors that are hesitant to prescribe it to more patients. theoretically if all patients stayed with regimen, the TRX should by now be multiples of magnitude larger than NRX, but it is not. This is not kind of a drug that patients take for 30 days and they are cured, it is a maintenance drug, if they stop taking it, it means it did not work for them. I think we are hoping for success, but prescription trends are telling us to forget it, with that said, if prescription trends get strong, I will be all over it, meanwhile a small number of shares so that I stay interested..

5.54+0.18(+3.36%)Jun 29 4:02 PMEDT